Management of bone complications in patients with genitourinary malignancies.
Management of bone complications in patients with genitourinary malignancies.
Urol Oncol. 2019 Oct 29;:
Authors: Ballon-Landa E, Panian J, Derweesh IH, McKay RR
Abstract
Skeletal metastases are common in genitourinary malignancies-including prostate cancer, renal cell carcinoma, and urothelial cancer-and portend significant morbidity and poor prognosis. The presence of skeletal metastases can result in decreased quality of life and increased morbidity. Strategies can be employed to prevent bone-related complications including lifestyle modifications and dietary supplementation. Additionally, pharmacologic agents exist to prevent bone loss and may be appropriate for patients at high risk of fragility-related or skeletal complications, such as pathologic fracture related to bone metastases. Finally, advancement in effective systemic treatments, particularly novel hormone-targeted agents and immunotherapies, may limit the morbidity of advanced disease and delay the onset of skeletal-related complications.
PMID: 31676279 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Ballon-Landa E, Panian J, Derweesh IH, McKay RR Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Diets | Hormones | Immunotherapy | Kidney Cancer | Nutrition | Orthopaedics | Prostate Cancer | Renal Cell Carcinoma | Science | Urology & Nephrology